Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090129 · ClinicalTrials.gov registry record · Phase 3
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
NCT00090129: Clinical Trial Phase 3 study, sponsored by EMD Serono.
NCT00090129 is a Phase 3 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 854 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00090129, a Phase 3 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
Study Summary
The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment period, depending on FT period response, and a 4-week safety follow-up (FU) period. The purpose of this study is to evaluate the safety and efficacy of onercept, to be administered as 150 milligram (mg) three times a week, compared to matching placebo, for the induction of remission in subjects with moderate to severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Onercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Why NCT00090129 stopped before completion
NCT00090129 is an interventional study that assigns participants to a tested intervention. The registered 854 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00090129 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00090129 about?
NCT00090129 is a clinical study titled "Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis". The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment period, depending on FT period response, and a 4-week safety follow-up...
What is the current status of trial NCT00090129?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2004-09. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00090129?
The interventions under investigation include: Placebo (DRUG), Onercept (DRUG).
Who is sponsoring clinical trial NCT00090129?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00090129's enrollment target sits among peer trials
854 384th of 2000 higher than 1,616 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia